Singapor - Ingliż - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - gadopentetic acid, dimeglumine salt - injection - 469 mg/ml - gadopentetic acid, dimeglumine salt 469 mg/ml

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: pentetate meglumine; water for injections; meglumine - using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement: . in intracranial and spinal lesions in adults and children with abnormal blood-brain barrier, or abnormal vascularity; . in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis). indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pan

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 aug 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: pentetate meglumine; meglumine; water for injections - indications as at 30 aug 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: meglumine; pentetate meglumine; water for injections - indications as 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) - solution for injection - 469 mg/ml - active: meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) excipient: meglumine pentetic acid water for injection

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - dimeglumine gadopentetate -